Allianz Asset Management
SPRY icon

Allianz Asset Management’s ARS Pharmaceuticals SPRY Stock Holding History

Allianz Asset Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-26,000
Closed -$261K – 2089
2025
Q3 		$261K Sell
26,000
-10,600
-29% -$152K ﹤0.01% 1928
2025
Q2 		$639K Buy
+36,600
New +$528K ﹤0.01% 1770

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Allianz Asset Management's SPRY Position: Q4 2025 in Review

Allianz Asset Management sold out of ARS Pharmaceuticals (SPRY) in Q4 2025, closing a stake of 26,000 shares — an estimated $261K sold.

Allianz Asset Management first reported a position in SPRY in Q2 2025 and held it in 2 quarters. The position peaked at $639K in Q2 2025. 190 funds tracked by Wall St. Rank hold SPRY as of Q4 2025.

  • Allianz Asset Management reported no remaining ARS Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Allianz Asset Management sold 26,000 ARS Pharmaceuticals shares in Q4 2025, an estimated $261K.
  • Allianz Asset Management first reported a position in ARS Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Allianz Asset Management's ARS Pharmaceuticals position peaked at $639K in Q2 2025.
  • 190 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2025.

Based on Allianz Asset Management's 13F filing for Q4 2025, filed 11 Feb 2026.